| Initiative | Owner | Progress | Status | Target |
|---|---|---|---|---|
| Enterprise Platform Launch | CPO | 82% |
ON TRACK | Aug 15 |
| International Expansion · EMEA | COO | 64% |
ON TRACK | Sep 30 |
| Series C Fundraise | CEO / CFO | 55% |
WATCH | Q4 2026 |
| Margin Expansion Program | CFO | 71% |
ON TRACK | FY26 EXIT |
| AI Capability Build-out | CTO | 48% |
WATCH | Q4 2026 |
| SOC 2 Type II · Renewal | CISO | 32% |
AT RISK | Jul 30 |
| Signal | Source | Δ | |
|---|---|---|---|
| SOC 2 renewal timeline slipping | Initiatives | -18d | |
| 2 enterprise accounts in renewal risk | CS Health | $1.4M ARR | |
| Sales cycle lengthening · enterprise | Pipeline | +11d | |
| Engineering hiring 3 mo behind plan | HRIS | -12 FTE | |
| Gross margin expansion accelerating | Finance | +180 bps | |
| NPS up 6 points · Mid-Market | Support | +6 |
The quarter is tracking ahead of plan on revenue (+3.2% to budget) and margin (+220 bps), driven by stronger mid-market wins and continued operating leverage in G&A. EBITDA conversion at 21.5% is the strongest in eight quarters.
Two items require attention. SOC 2 renewal is 18 days behind schedule with a hard customer-contract dependency in October; recommend the CISO escalates an external auditor swap this week. Two enterprise accounts representing $1.4M ARR have triggered renewal-risk scoring after support-ticket spikes — CS has owners assigned but no recovery plan logged yet.
Suggested board talking points: margin trajectory, Series C narrative around NRR (118%), the SOC 2 mitigation, and the AI capability build-out timeline (currently 48% complete vs. plan).